Tozuleristide (BLZ-100)

About Blaze Bioscience

Blaze Bioscience is a clinical-stage biotech developing targeted imaging agents to illuminate cancer cells during surgery. Its lead candidate, tozuleristide (BLZ-100), is an investigational product designed to help surgeons achieve complete tumor resection by providing real-time, direct visualization of malignant tissue. Founded in 2010 and built on technology from the Fred Hutchinson Cancer Research Center, the company is targeting significant unmet needs in surgical oncology, starting with brain and breast cancers. Blaze remains privately held and is led by a management team with extensive experience in biotech development, finance, and clinical operations.

About Blaze Bioscience

Blaze Bioscience is a clinical-stage biotech developing targeted imaging agents to illuminate cancer cells during surgery. Its lead candidate, tozuleristide (BLZ-100), is an investigational product designed to help surgeons achieve complete tumor resection by providing real-time, direct visualization of malignant tissue. Founded in 2010 and built on technology from the Fred Hutchinson Cancer Research Center, the company is targeting significant unmet needs in surgical oncology, starting with brain and breast cancers. Blaze remains privately held and is led by a management team with extensive experience in biotech development, finance, and clinical operations.

Therapeutic Areas